Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Initial treatment patterns and survival outcomes in patients with Mantle Cell Lymphoma in the era of BTK inhibitors: A multicenter real-world study

View Full Paper
Ask AI
Bookmark
Share

Authors

DWDepei WuTYTao YouJZJin Zhou

Discussion

Loading...

Member takes

Overview

Multicenter real-world study highlights BTK inhibitors and rituximab as key factors in survival outcomes for mantle cell lymphoma.

Key Points

  • To characterize treatment patterns and survival outcomes of patients with mantle cell lymphoma in clinical practice.
  • Retrospective analysis of 234 patients from four major hematology centers in China
  • Assessment of initial treatment approaches and survival outcomes over a follow-up of 27 months
  • Evaluation of factors influencing overall survival
  • 93.6% received Rituximab as first-line therapy
  • 2-year overall survival rate increased with BTK inhibitors (89.4% vs. 77.8%)
  • ASCT showed 2-year OS rates of 94.7% vs. 80.1% for non-transplant recipients

Cite This Study

Wu et al. (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d1fbhttps://doi.org/10.1182/blood-2025-7100
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Treatment patterns and survival outcomes in patients with Mantle Cell Lymphoma: Interim report of the Asia-Pacific multinational prospective registry study2025 · 1 citations
  2. 2Real-world treatment and safety outcomes of patients with Mantle Cell Lymphoma in the United States2025
  3. 3Real-world treatment utilization, sequencing, and outcomes in Mantle Cell Lymphoma: Emerging treatment patterns in the United States2025
  4. 4Real-world treatment patterns, patient characteristics, and outcomes of cbtki-based therapies amongst a contemporary cohort of patients with R/R MCL in the United States2025
  5. 5“B” symptoms and CBV conditioning negatively impact survival in mantle cell lymphoma patients undergoing autologous stem cell transplantation2025 · 1 citations